Oral immunopotentiator of plant vesicle and its preparation method and application
By modifying plant vesicles with gelatin and calcium phosphide, and combining them with FP127, the problems of stability and immune activation of plant vesicles in the gastrointestinal environment have been solved, achieving synergistic enhancement of stability and immune activation in the gastrointestinal tract, which is suitable for clinical translation into oral delivery systems.
Patent Information
- Application Number
- CN202610367457.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-24
- Publication Date
- 2026-06-26
Smart Images

Figure CN122272827A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of plant vesicle technology, specifically to an oral immune enhancer of plant vesicles, its preparation method, and its application. Background Technology
[0002] Oral administration has become one of the ideal routes of administration for immunostimulants due to its convenience, high patient compliance, and non-invasive nature. However, oral immunostimulants face multiple challenges during in vivo delivery: on the one hand, the highly acidic environment of the gastrointestinal tract (gastric pH 1.0-3.0) and digestive enzyme systems (such as pepsin and trypsin) can lead to the degradation and inactivation of active ingredients, reducing bioavailability; on the other hand, the intestinal mucosal barrier makes it difficult for active ingredients to effectively penetrate the mucosal layer and precisely target immune cells to exert their effects. Furthermore, existing immunostimulants often rely on chemically synthesized adjuvants or microbial-derived components, which have problems such as poor biocompatibility and the potential to induce immune tolerance or excessive inflammatory responses.
[0003] Plant vesicles, as natural nanocarriers derived from medicinal and edible plant tissues, are rich in active ingredients such as saponins, polysaccharides, and flavonoids. They possess advantages such as low immunogenicity, excellent biocompatibility, and inherent immunomodulatory activity, showing great potential in the field of oral drug delivery. Among them, plant vesicles derived from ginseng, mulberry leaves, and turmeric can exert therapeutic effects by regulating intestinal flora homeostasis, modulating immune cell function, and repairing the mucosal barrier. Moreover, the raw materials are natural and non-toxic, meeting the biosafety requirements of oral administration. However, oral delivery of natural plant vesicles faces multiple physiological obstacles: the acidic environment of the stomach easily leads to the destruction of their membrane structure and degradation of active ingredients; the adhesion and clearance effects of the intestinal mucus layer reduce their mucosal permeation efficiency; and the intestinal enzymatic hydrolysis system further aggravates vesicle inactivation, resulting in extremely low bioavailability, which seriously limits their clinical translation.
[0004] To address the stability issues of plant vesicles, existing technologies often employ polymer coatings (such as polylactic acid-glycolic acid copolymers and chitosan) or lipid modification. However, these materials suffer from several drawbacks: First, some synthetic polymers exhibit poor biodegradability, and long-term accumulation may trigger tissue irritation. Second, while natural polysaccharides like chitosan have good biocompatibility, their resistance to gastric acid is limited, leading to protonation and swelling degradation in the stomach. Third, the coating process is complex, requiring organic solvents or high temperatures, which can easily damage the active components of plant vesicles. Furthermore, existing technologies often focus solely on improving stability without synergistically designing stability optimization with enhanced immune activation efficiency, making it difficult to achieve a complete "survival-targeting-activation" functional chain. Existing immunomodulators based on plant exosomes lack specific acid-resistant modifications for the gastric acid environment; other studies have used liposomes to encapsulate immune adjuvants, but the preparation process of liposomes is complex, and the synergistic immune enhancement mechanism with plant vesicles remains unclear.
[0005] Therefore, developing a plant vesicle-based oral immune enhancer that combines gastric acid tolerance, improved stability, and enhanced immune activation to overcome the physiological barriers of oral delivery and achieve efficient delivery and enhanced activity of plant vesicles is of great significance for promoting the development of oral nanomedicine delivery systems. Summary of the Invention
[0006] The purpose of this invention is to address the aforementioned shortcomings by providing an oral immune enhancer of plant vesicles, its preparation method, and its application. By modifying the surface of plant vesicles with calcium phosphide and gelatin, the stability of plant vesicles in the gastrointestinal environment is significantly improved, and the maturation and immune activation functions of dendritic cells are synergistically enhanced. The invention also provides a preparation method and application, enabling multi-scenario adaptation for intestinal inflammation treatment, oral tumor immunotherapy, and mucosal repair, thus providing a novel, highly efficient, and safe formulation for oral immunotherapy.
[0007] To solve the above-mentioned technical problems, the present invention adopts the following technical solution: a plant vesicle-based oral immune enhancer, wherein the enhancer comprises plant vesicles modified with modified gelatin as a matrix and loaded with calcium phosphide; The plant vesicle has a core-shell structure, where the core is a plant vesicle and the shell is a calcium phosphate mineralization layer.
[0008] Furthermore, the plant vesicles are one or more mixed tissues of ginseng, mulberry leaf, turmeric, and astragalus.
[0009] Furthermore, the modified gelatin is one or a mixture of methacrylated gelatin and chitosan-modified gelatin.
[0010] Furthermore, the surface of the shell adsorbs 0.5-2% fluorinated Pluronic (FP127) by mass fraction.
[0011] A method for preparing a plant vesicle-based oral immune enhancer includes the following steps: S1. Extraction and purification of plant vesicles: One or more mixed tissues of ginseng, mulberry leaf, turmeric, and astragalus are taken and prepared by centrifugation to obtain plant vesicles; S2, Preparation of calcium phosphide-modified plant vesicles: The plant vesicles prepared in S1 were prepared into a vesicle suspension, then calcium chloride solution and sodium phosphide solution were added, and centrifuged after the reaction. The precipitate was collected and resuspended in fluorinated Pluronic PBS solution, and then centrifuged to obtain calcium phosphate-modified plant vesicles with fluorinated Pluronic (FP127) adsorbed on the surface. S3. Preparation of oral immune enhancers: S3.1 Dissolve the modified gelatin in deionized water and stir in a water bath at 40-60℃ until completely dissolved to prepare a gelatin solution with a mass fraction of 8-15%. S3.2 Add the calcium phosphate-modified plant vesicles with surface-adsorbed fluorinated Pluronic (FP127) obtained in S2 to the gelatin solution, and ultrasonically disperse them for 10-20 min at a power of 100-200 W under ice bath conditions to disperse the vesicles in the gelatin matrix. S3.3 Pour the mixed solution into a spherical mold and crosslink it under 365nm ultraviolet light for 8-15 minutes, achieving a crosslinking strength of 15-20mW / cm. 2 This forms hydrogel microspheres; S3.4. The hydrogel microspheres were freeze-dried and spray-coated to obtain an oral immune enhancer.
[0012] Furthermore, step S1 specifically includes the following steps: S1.1 Take one or more of fresh ginseng, mulberry leaves, turmeric or astragalus, rinse three times with deionized water, and then place them on sterile filter paper to absorb the surface moisture. S1.2 Add phosphate buffer pre-cooled to 4℃ at a ratio of 1:10-20 g / mL and homogenize three times to completely break down the tissue and obtain a homogenate. S1.3. The homogenate was also filtered using a 200-mesh sterile filter cloth, and then the filtrate was centrifuged and the supernatant was collected. S1.4 After resuspending the precipitate with PBS buffer, add the resuspended solution to a sucrose density gradient centrifuge tube and centrifuge at 120000g for 120min. Collect the fraction with a density range of 1.1-1.2g / mL to obtain plant vesicles.
[0013] Furthermore, in S1.3, the specific steps for centrifuging the filtrate are as follows: the filtrate is centrifuged at 800g for 10 min, 3000g for 20 min, and 10000g for 30 min, the supernatant is collected, and then the supernatant is transferred to an ultracentrifuge tube and centrifuged at 100000g for 70 min. The supernatant is then discarded.
[0014] Furthermore, step S2 specifically includes the following steps: S2.1 Resuspend the plant vesicles obtained in S1 in Tris-HCl buffer to prepare a vesicle suspension with a concentration of 0.5-2.0 mg / mL; S2.2. Add 0.01-0.05 mol / L calcium chloride solution dropwise to the vesicle suspension. The Ca in the solution... 2+ The mass ratio of the vesicle to the vesicle is 1:5-1:20, and the mixture is magnetically stirred for 30 minutes. S2.3. Add 0.01-0.03 mol / L sodium phosphide solution dropwise, and maintain the pH of the system at 7.0-7.5 with 0.1 mol / L NaOH solution. Stir at 37℃ for 2 hours. S2.4 After the reaction is complete, centrifuge at 12000g for 15min, collect the precipitate, and wash it 3 times with PBS buffer. S2.5. The precipitate was resuspended in a PBS solution containing fluorinated Pluronic (FP127), incubated at room temperature for 1 h, and centrifuged at 10000g for 10 min to obtain calcium phosphate-modified plant vesicles with fluorinated Pluronic (FP127) adsorbed on the surface.
[0015] Furthermore, in step S3.1, if the modified gelatin is methacrylated gelatin, a photoinitiator with a concentration of 0.5-2.0 mg / mL is added during the preparation of the gelatin solution.
[0016] Application of a plant vesicle-based oral immune enhancer, wherein the immune enhancer is used in the preparation of oral intestinal inflammation treatment drugs, oral tumor immunotherapy drugs, intestinal mucosal repair materials or immune aging regulation agents; The oral tumor immunotherapy drug is used to treat ulcerative colitis and Crohn's disease, and is in the form of oral microspheres or capsules; The oral tumor immunotherapy drug is used to treat colon cancer and achieves anti-tumor effects by regulating the intestinal immune microenvironment.
[0017] Compared with the prior art, the present invention has the following beneficial effects: 1. This invention provides plant vesicles modified with calcium phosphide as a matrix and combined with FP127 to achieve multiple protections and regulation, breaking through the physiological barrier of oral delivery. It establishes a triple mechanism of "inherent vesicle activity + adjuvant enhancement + targeted active ingredient". The immune enhancer is structurally stable in the gastric acid environment and rapidly swells and degrades in the neutral intestinal environment, achieving targeted release of plant vesicles and active ions. The active ingredients of plant vesicles and the degradation ions of calcium phosphide promote DC maturation and T cell activation, resulting in a therapeutic effect superior to single-component systems. 2. This invention employs conventional processes such as homogenization, graded centrifugation, and gentle stirring, eliminating the need for organic solvents and extreme conditions throughout the process. The steps are controllable, and the raw materials are widely available (ginseng, mulberry leaves, turmeric, astragalus, etc. are common medicinal plants), significantly reducing production difficulty and cost. It is also suitable for the treatment needs of common clinical diseases such as colon cancer and ulcerative colitis, and is suitable for the clinical transformation and industrial promotion of oral nanomedicine delivery systems. Attached Figure Description
[0018] The accompanying drawings, which form part of this application, are used to provide a further understanding of the invention. The illustrative embodiments of the invention and their descriptions are used to explain the invention and do not constitute an undue limitation of the invention. In the drawings: Figure 1 This is a flowchart illustrating the preparation process of an embodiment of the present invention.
[0019] Figure 2 This is a schematic diagram comparing ginseng vesicles with calcium phosphide-modified ginseng vesicles according to an embodiment of the present invention.
[0020] Figure 3 This is a scanning electron microscope image and a schematic diagram of the particle size distribution of an immune enhancer according to an embodiment of the present invention.
[0021] Figure 4 This is a schematic diagram illustrating the effect of ginseng vesicles and immune enhancers on a gastrointestinal simulation experiment according to an embodiment of the present invention.
[0022] Figure 5 This is a flow cytometry atlas of an immune enhancer used in vitro to verify the immune response, according to an embodiment of the present invention.
[0023] Figure 6 This is an in vivo experimental diagram of an immune enhancer for the treatment of ulcerative colitis according to an embodiment of the present invention.
[0024] Figure 7 This is a schematic diagram of an in vivo colon cancer treatment experiment using an immune enhancer according to an embodiment of the present invention.
[0025] Figure 8 This is a schematic diagram of a long-term biosafety experiment of an immune enhancer according to an embodiment of the present invention. Detailed Implementation
[0026] The technical solutions of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. Unless otherwise specified, the embodiments and features in the embodiments of this application can be combined with each other. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.
[0027] Example 1: Combination Figures 1-3 The present invention relates to a plant vesicle-based oral immune enhancer, wherein the enhancer comprises plant vesicles modified with calcium phosphide and supported on a modified gelatin matrix; the plant vesicles have a core-shell structure, wherein the core is a plant vesicle and the shell is a calcium phosphide mineralization layer.
[0028] The plant vesicles are ginseng tissue; the modified gelatin is methacrylated gelatin with a degree of substitution of 30%; the surface of the shell is adsorbed with 0.5-2% fluorinated Pluronic (FP127).
[0029] A method for preparing a plant vesicle-based oral immune enhancer includes the following steps: S1. Extraction and purification of plant vesicles: S1.1 Take fresh ginseng tissue, rinse it three times with deionized water, and then place it on sterile filter paper to absorb the surface moisture. S1.2 Add phosphate buffer (0.1M PBS buffer containing 0.15M NaCl) pre-cooled to 4℃ at a ratio of 1:15 g / mL and homogenize 3 times to completely disrupt the tissue and obtain a homogenate. S1.3. The homogenate was also filtered using a 200-mesh sterile filter cloth. The filtrate was then centrifuged at 800g for 10 min, 3000g for 20 min, and 10000g for 30 min. The supernatant was collected and then transferred to an ultracentrifuge tube. The tube was centrifuged at 100000g for 70 min. The supernatant was then discarded. S1.4 After resuspending the precipitate in 5 mL of PBS buffer (pH 7.4), add the resuspended solution to a sucrose density gradient centrifuge tube (sucrose densities of 1.0, 1.1 and 1.2 g / mL), centrifuge at 120000g for 120 min, and collect the fractions in the density range of 1.1-1.2 g / mL to obtain ginseng vesicles. The particle size was measured to be about 150 nm by a Malvern particle size analyzer. S2, Preparation of calcium phosphide-modified plant vesicles: S2.1. Resuspend the ginseng vesicles obtained in S1 in Tris-HCl buffer and bring the volume to 10 mL to prepare a ginseng vesicle suspension with a concentration of 1.0 mg / mL. S2.2. Add a 0.2 mol / L calcium chloride solution dropwise to the ginseng vesicle suspension. The Ca in the solution... 2+ The mass ratio of the vesicle to the vesicle was 1:10, and the mixture was magnetically stirred for 30 minutes. S2.3. Add 0.8 mL of 0.015 mol / L sodium phosphide solution dropwise, and maintain the pH of the system at 7.2 with 0.1 mol / L NaOH solution. Stir at 37℃ for 2 h. S2.4 After the reaction is complete, centrifuge at 12000g for 15min, collect the precipitate, and wash it 3 times with PBS buffer. S2.5. The precipitate was resuspended in 5 mL of PBS solution containing 0.1 mg / mL fluorinated Pluronic (FP127), incubated at room temperature for 1 h, and centrifuged at 10000 g for 10 min to obtain calcium phosphate modified ginseng vesicles with fluorinated Pluronic (FP127) adsorbed on the surface. TEM observation showed that the thickness of the mineralization layer was 5-10 nm. S3. Preparation of oral immune enhancers: S3.1 Dissolve the modified gelatin in deionized water. The modified gelatin is methacrylated gelatin. Prepare a 10% GelMA solution. During the preparation of the gelatin solution, add 10 mg of photoinitiator I2959 with a concentration of 2.0 mg / mL and stir in a water bath at 40-60℃ until completely dissolved. S3.2 Add 0.5 mg of calcium phosphate-modified human vesicles with surface-adsorbed fluorinated Pluronic (FP127) obtained in S2 to a gelatin solution, and sonicate for 15 min at a power of 150 W under ice bath conditions to disperse the vesicles in the gelatin matrix. S3.3. Pour the mixed solution into a spherical mold (500 μm in diameter) and place it under 365 nm ultraviolet light for 10 min for crosslinking, achieving an intensity of 15 mW / cm. 2 This forms hydrogel microspheres; S3.4. Subsequently, it was freeze-dried at -80℃ for 36 h, and then spray-coated with hydroxypropyl methylcellulose to obtain an oral immune enhancer.
[0030] Application of a plant vesicle-based oral immune enhancer, wherein the immune enhancer is used in the preparation of oral intestinal inflammation treatment drugs, oral tumor immunotherapy drugs, intestinal mucosal repair materials or immune aging regulation agents; The oral tumor immunotherapy drug is used to treat ulcerative colitis and Crohn's disease, and is in the form of oral microspheres or capsules; after oral administration, the immune enhancer, with hydroxypropyl methylcellulose coating and calcium phosphide mineralization layer, synergistically resists gastric acid erosion, and the gelatin matrix swells and slowly releases mineralized vesicles in the intestinal environment; the vesicles degrade and release plant active ingredients and ions, regulate DC maturation, reduce the secretion of pro-inflammatory factors such as TNF-α, increase the level of anti-inflammatory factor IL-10, and repair the damaged intestinal mucosal barrier; The oral immunotherapy drug is used to treat colon cancer, achieving anti-tumor effects by regulating the intestinal immune microenvironment. After oral administration, the immune enhancer swells and degrades at the target site in the colon, releasing calcium phosphide mineralized plant vesicles. These vesicles precisely target tumor tissue and tumor-associated intestinal mucosa. The active components of the plant vesicles (such as ginsenoside Rg3 and curcumin derivatives) can directly inhibit colon cancer cell proliferation and induce cancer cell apoptosis, while simultaneously regulating tumor-associated macrophage polarization and activating dendritic cell maturation. The calcium phosphide degradation releases Ca...2+ Phosphine can regulate the pH of the tumor microenvironment, inhibit tumor angiogenesis, activate the gut-associated lymphoid tissue (GALT) immune response, and promote CD8. + Cytotoxic T lymphocyte infiltration enhances anti-tumor immune memory effects and reduces the risk of recurrence and metastasis of colon cancer.
[0031] In vitro gastrointestinal stability testing of immune enhancers: The immune enhancer prepared in Example 1 was placed in simulated gastric juice (pH 2.0, containing pepsin) and simulated intestinal juice (pH 7.4, containing pancreatin), respectively, and incubated at 37°C with shaking for 2 h and 4 h. The plant vesicle protein profile was analyzed by combined detection of SDS-PAGE and BCA. Simulated gastric juice (SGF): Take 23.4 mL of concentrated hydrochloric acid and dilute it to 100 mL with deionized water; take 3.5 mL of this diluted solution and mix it with 800 mL of water and 10 g of pepsin until completely dissolved, then make up to 1000 mL with deionized water and adjust the pH to 2.0. Simulated intestinal fluid (SIF): Dissolve 6.8g of potassium dihydrogen phosphate (KH2PO4) in 500mL of deionized water, and adjust the pH to 6.8 with 0.1mol / L sodium hydroxide (NaOH); separately dissolve 10g of trypsin in an appropriate amount of water, mix with the above phosphate solution, and make up to 1000mL with deionized water. like Figure 4 As shown, (A) shows the effect of SDS-PAGE analysis on the protein profile of ginseng vesicles and immune enhancers after treatment with simulated gastrointestinal liquid; (B) shows the effect of treatment with simulated gastrointestinal liquid on the total protein content of ginseng vesicles by BCA method (n=3). The results showed that after 2 hours of incubation with simulated gastric juice, the retention rate of characteristic proteins in vesicles was 82.3%, which was significantly higher than the 45.6% in the unmineralized vesicle group; after 4 hours of incubation with simulated intestinal juice, the protein retention rate was 78.5%, indicating that the surface immune enhancer had excellent gastrointestinal stability.
[0032] In vitro activation of immunity by immune enhancers: Immunostimulants induce DC maturation and T cell activation in vitro, such as Figure 5 As shown, primary dendritic cells (DCs) were extracted from mice and co-incubated with the control group (PBS) and the immune enhancer group for 24 h. (A) shows mature dendritic cells (CD80) after treatment with the immune enhancer. + CD86 + (A) A representative flow cytometry atlas of DCs treated with an immunostimulant, seeded in the upper chamber and co-cultured with T cells in the lower chamber overnight. T cell activation was analyzed 24 hours later, and CD8+ was observed after immunostimulant treatment. +Representative flow cytometry atlas of T cells; results showed that the effect of using immune enhancers was far superior to that of the control group.
[0033] In vivo clinical trial of immune enhancers for the treatment of ulcerative colitis: A DSS-induced ulcerative colitis model was established in BALB / c mice. Both the model group (PBS) and the immune enhancer group were administered orally once daily for 7 consecutive days. After the experiment, the colonic pathological sections and inflammatory factor levels were detected. like Figure 6 As shown, (A) is a representative HE-stained pathological section of mouse colon tissue; (B) is the level of inflammatory factors in mouse serum, including TNF-α, IL-6 and IL-10. The results showed that the histopathological sections of the colon tissue of mice in the immune enhancer group were similar to those in the normal group, and the mucosal structure was basically restored to normal. The TNF-α level was 284.4 pg / mL, which was significantly lower than that in the control model group (673.6 pg / mL), the IL-6 level was 293.18 pg / mL, which was significantly lower than that in the model group (49.62 pg / mL), and the IL-10 level increased to 17.96 pg / mL, indicating that the immune enhancer has excellent therapeutic effect on colitis.
[0034] Oral immunostimulants for colon cancer treatment and biosafety studies: 1. In vivo colon cancer treatment experiment: A subcutaneous xenograft model of CT26 colon cancer cells was established in BALB / c mice. When the tumor volume reached 80-100 mm³, the mice were randomly divided into 4 groups (n=5): model group (PBS), unmineralized vesicle + gelatin group, mineralized vesicle group, and immune enhancer group. The drugs were administered orally once daily for 21 consecutive days. Tumor volume and mouse body weight were measured every 3 days. After the experiment, the tumor tissue was dissected, the tumor inhibition rate was calculated, and CD8 in the tumor tissue was detected. + T cell infiltration and related cytokine levels; like Figure 7 As shown, (A) is the tumor inhibition rate of colon cancer in mice under different treatment groups; (B) is an immunofluorescence section of representative CD8 T cells in tumor tissue; (C) is the level of TNF-α and IFN-γ cytokines in mouse tumors detected by ELISA. The results showed that the tumor inhibition rate in the immune enhancer group was 71.6%, significantly higher than that in the unmineralized vesicle + gelatin group (15.4%) and the mineralized vesicle group (12.8%). The CD8+ level in the tumor tissue of the immune enhancer group was also significantly higher. + The T cell infiltration rate was 4.3 times that of the model group, and the levels of TNF-α and IFN-γ were significantly increased, significantly higher than those of other groups; moreover, the mice in the immune enhancer group had normal diet and activity.
[0035] 2. Long-term biosafety experiments: Twenty SPF-grade ICR mice were randomly divided into two groups (n=10): a control group (saline) and an immune enhancer group (oral administration, 100 mg / kg). The mice were administered the drug once daily for 30 consecutive days. After the experiment, liver and kidney function and organ indices were measured. Pathological sections of the heart, liver, spleen, lungs, kidneys, and colon were analyzed (e.g., ...). Figure 8 (As shown).
[0036] The results showed that the liver and kidney function (lactate dehydrogenase, alanine aminotransferase, aspartate aminotransferase, and blood urea nitrogen) indicators of mice in the immune enhancer group were all within the normal range and there was no significant difference compared with the control group; the indices of each organ were normal, and the pathological sections showed no inflammatory infiltration, necrosis, or abnormal proliferation, confirming that the immune enhancer has no obvious toxic side effects when taken orally for a long time, and its biosafety meets the requirements for clinical application.
[0037] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above, and that the invention can be implemented in other specific forms without departing from the spirit or essential characteristics of the invention. Therefore, the embodiments should be considered in all respects as exemplary and non-limiting, and the scope of the invention is defined by the appended claims rather than the foregoing description. Thus, it is intended that all variations falling within the meaning and scope of equivalents of the claims be included within the present invention.
Claims
1. A plant-based vesicle-based oral immune enhancer, characterized in that, The enhancer includes plant vesicles modified with calcium phosphide and based on modified gelatin. The plant vesicle has a core-shell structure, where the core is a plant vesicle and the shell is a calcium phosphate mineralization layer.
2. The plant-based vesicle-based oral immune enhancer according to claim 1, characterized in that, The plant vesicles are one or more mixed tissues of ginseng, mulberry leaf, turmeric, and astragalus.
3. The plant-based vesicle-based oral immune enhancer according to claim 1, characterized in that, The modified gelatin is one or a mixture of methacrylated gelatin and chitosan-modified gelatin.
4. The plant-based vesicle-based oral immune enhancer according to claim 1, characterized in that, The surface of the shell is adsorbed with 0.5-2% fluorinated Pluronic.
5. A method for preparing a plant-based vesicle-based oral immune enhancer according to any one of claims 1-4, characterized in that, Includes the following steps: S1. Extraction and purification of plant vesicles: One or more mixed tissues of ginseng, mulberry leaf, turmeric, and astragalus are taken and prepared by centrifugation to obtain plant vesicles; S2, Preparation of calcium phosphide-modified plant vesicles: The plant vesicles prepared in S1 were prepared into a vesicle suspension, then calcium chloride solution and sodium phosphide solution were added, and after the reaction, the vesicles were centrifuged, the precipitate was collected and resuspended in fluorinated Pluronic PBS solution, and then centrifuged to obtain calcium phosphate-modified plant vesicles with fluorinated Pluronic adsorbed on the surface. S3. Preparation of oral immune enhancers: S3.1 Dissolve the modified gelatin in deionized water and stir in a water bath at 40-60℃ until completely dissolved to prepare a gelatin solution with a mass fraction of 8-15%. S3.2 Add the calcium phosphate-modified plant vesicles with surface-adsorbed fluorinated Pluronic obtained in S2 to the gelatin solution, and ultrasonically disperse them for 10-20 min at a power of 100-200 W under ice bath conditions to disperse the vesicles in the gelatin matrix. S3.3 Pour the mixed solution into a spherical mold and crosslink it under 365nm ultraviolet light for 8-15 minutes, achieving a crosslinking strength of 15-20mW / cm. 2 This forms hydrogel microspheres; S3.
4. The hydrogel microspheres were freeze-dried and spray-coated to obtain an oral immune enhancer.
6. The method for preparing the plant vesicle-based oral immune enhancer according to claim 5, characterized in that, S1 specifically includes the following steps: S1.1 Take one or more of fresh ginseng, mulberry leaves, turmeric or astragalus, rinse three times with deionized water, and then place them on sterile filter paper to absorb the surface moisture. S1.2 Add phosphate buffer pre-cooled to 4℃ at a ratio of 1:10-20 g / mL and homogenize three times to completely break down the tissue and obtain a homogenate. S1.
3. The homogenate was also filtered using a 200-mesh sterile filter cloth, and then the filtrate was centrifuged and the supernatant was collected. S1.4 After resuspending the precipitate with PBS buffer, add the resuspended solution to a sucrose density gradient centrifuge tube and centrifuge at 120000g for 120min. Collect the fraction with a density range of 1.1-1.2g / mL to obtain plant vesicles.
7. The method for preparing the plant vesicle-based oral immune enhancer according to claim 6, characterized in that, In S1.3, the specific steps for centrifuging the filtrate are as follows: centrifuge the filtrate at 800g for 10 min, at 3000g for 20 min, and at 10000g for 30 min, collect the supernatant, then transfer the supernatant to an ultracentrifuge tube, centrifuge at 100000g for 70 min, and discard the supernatant to obtain the final product.
8. The method for preparing the plant vesicle-based oral immune enhancer according to claim 5, characterized in that, S2 specifically includes the following steps: S2.1 Resuspend the plant vesicles obtained in S1 in Tris-HCl buffer to prepare a vesicle suspension with a concentration of 0.5-2.0 mg / mL; S2.
2. Add 0.01-0.05 mol / L calcium chloride solution dropwise to the vesicle suspension. The Ca in the solution... 2+ The mass ratio of the vesicle to the vesicle is 1:5-1:20, and the mixture is magnetically stirred for 30 minutes. S2.
3. Add 0.01-0.03 mol / L sodium phosphide solution dropwise, and maintain the pH of the system at 7.0-7.5 with 0.1 mol / L NaOH solution. Stir at 37℃ for 2 hours. S2.4 After the reaction is complete, centrifuge at 12000g for 15min, collect the precipitate, and wash it 3 times with PBS buffer. S2.
5. The precipitate was resuspended in a PBS solution containing fluorinated Pluronic, incubated at room temperature for 1 h, and centrifuged at 10000 g for 10 min to obtain calcium phosphate-modified plant vesicles with fluorinated Pluronic adsorbed on the surface.
9. The method for preparing the plant vesicle-based oral immune enhancer according to claim 5, characterized in that, In step S3.1, if the modified gelatin is methacrylated gelatin, a photoinitiator with a concentration of 0.5-2.0 mg / mL is added during the preparation of the gelatin solution.
10. The application of a plant-based vesicle-based oral immune enhancer according to any one of claims 1-4, characterized in that, The immune enhancer is used in the preparation of oral intestinal inflammation treatment drugs, oral tumor immunotherapy drugs, intestinal mucosal repair materials or immune aging regulation agents; The oral tumor immunotherapy drug is used to treat ulcerative colitis and Crohn's disease, and is in the form of oral microspheres or capsules; The oral tumor immunotherapy drug is used to treat colon cancer and achieves anti-tumor effects by regulating the intestinal immune microenvironment.
